Executive Market Assessment: The Sovereign Paradox The Russian pharmaceutical sector currently operates within a paradigm of aggressive state-managed isolationism, creating […]

For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the $300 billion patent cliff 1. The Strategic

The global pharmaceutical industry is running out of time. Between 2024 and 2030, roughly $200 billion in branded drug revenue

1. What Patent Use Codes Are and Why They Cost the Healthcare System $3.5 Billion per Year A patent use

Why Patent Data Outperforms Every Other Pharma Signal A company’s balance sheet is a photograph of last quarter. Its clinical

1. The Market Imperative: Biologics Cost 46% of U.S. Drug Spend at Less Than 2% of Volume Biologic drugs generated

Section 1: The Patent as a Balance Sheet Asset A pharmaceutical patent is not a legal formality. It is the

Introduction: The End of the Free Pricing Era The pharmaceutical industry has long operated under a unique social contract: invest

1. Why Extrapolation Is the Most Valuable Two Words in Biosimilar Development Biologics occupy a peculiar place in the pharmaceutical